Cosette Pharmaceuticals announces the launch of Griseofulvin Oral Suspension, 125 mg/5 mL.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    Chemical Business NewsBase (UK), December 6, 2022, 2pp
  • Additional Information
    • Abstract:
      Cosette Pharmaceuticals Inc began shipping Griseofulvin Oral Suspension, 125 mg/5 mL (0713-0850-04) into all channels in the United States (US). This launch will provide much needed access to patients and providers for a product which has been supply constrained. The finished product will be manufactured in the US. According to IQVIA, US market annual sales for the 12 months ended Oct 2022 for Griseofulvin Oral Suspension, 125 mg/5 mL is estimated to be approximately $12 M...